Enveric Biosciences
Yahoo Finance • last month
Enveric Biosciences GAAP EPS of -$10.81
* Enveric Biosciences press release [https://seekingalpha.com/pr/20308638-enveric-biosciences-reports-third-quarter-2025-financial-and-corporate-results] (ENVB [https://seekingalpha.com/symbol/ENVB]): Q3 GAAP EPS of -$10.81. * The net... Full story
Yahoo Finance • 2 months ago
AbbVie ends in green six straight sessions of declines
[AbbVie] hapabapa AbbVie (NYSE:ABBV [https://seekingalpha.com/symbol/ABBV]) snapped six consecutive sessions of losses on Thursday as the stock ended 0.29% lower at $226.87. Since October 8, the stock has closed in the red every day unti... Full story
Yahoo Finance • 2 months ago
AbbVie could face patent battle over depression asset gained in Gilgamesh deal
[Patent infringement] TheaDesign * Microcap Enveric Biosciences (NASDAQ:ENVB [https://seekingalpha.com/symbol/ENVB]) is threatening to take legal action against AbbVie (NYSE:ABBV [https://seekingalpha.com/symbol/ABBV]) as it believes th... Full story
Yahoo Finance • 2 months ago
Enveric Biosciences hires Fish & Richardson to defend patent tied to AbbVie deal
Investing.com -- Enveric Biosciences (NASDAQ: ENVB) has hired prominent intellectual property law firm Fish and Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals, which earlier this year agree... Full story
Yahoo Finance • 2 months ago
Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal
EB-003, Enveric’s lead product candidate, is protected by a different patent family that includes an issued U.S. patent and pending U.S. and international patents, all of which are separate and distinct from the patent that appears relevan... Full story
Yahoo Finance • 5 months ago
Enveric Biosciences receives second patent allowance for PTSD drug
CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ:ENVB) announced Wednesday it has received a second Notice of Allowance from the United States Patent and Trademark Office for compounds in its EVM401 Series, expanding its intellectual propert... Full story
Yahoo Finance • 6 months ago
Enveric's lead drug candidate shows additional receptor activity
CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ:ENVB), a biotechnology company currently trading at $1.25 per share and showing signs of being undervalued according to InvestingPro Fair Value metrics, announced Tuesday that its lead drug ca... Full story
Yahoo Finance • 2 years ago
Diamond Equity Research Initiates Coverage on Enveric Biosciences Inc. (NASDAQ: ENVB)
NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Enveric Biosciences Inc. (NASDAQ: ENVB). The in-depth 23-... Full story
Yahoo Finance • 3 years ago
10 Most Promising Psychedelic Stocks According To Analysts
In this article, we discuss 10 most promising psychedelic stocks according to analysts. If you want to see more stocks in this selection, check out 5 Most Promising Psychedelic Stocks According To Analysts. Psychedelic drugs encompass a r... Full story
